ArticleBritish journal of cancer1988
An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma.
Article in British journal of cancer, 1988. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 203 citations in OpenAlex.
- Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53.Annals of surgery · 2001Trial
- Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast CancerAsian Pacific journal of cancer prevention : APJCP · 2017Article
- Article
- Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor.SpringerPlus · 2014Article
- HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?British journal of cancer · 2007Article
- HER-2/neu oncogene amplification by chromogenic in situ hybridization in 130 breast cancers using tissue microarray and clinical follow-up studies.Journal of Korean medical science · 2004Article
- Significance of immunohistochemical c-ErbB-2 product localisation pattern for prognosis in human breast cancer.Pathology oncology research : POR · 2001Article
- Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer.British journal of cancer · 1999Article
- Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer.British journal of cancer · 1997Article
- Flow Cytometric Assay of c-erbB-2 Protein in Fine Needle Aspirates of Fresh and Frozen Human Breast Cancer Tissues.Breast cancer (Tokyo, Japan) · 1996Article
- Human papilloma virus DNA: a factor in the pathogenesis of mammary Paget's disease?Breast cancer research and treatment · 1996Article
- Biological indices in the assessment of breast cancer.Clinical molecular pathology · 1995Article
- Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay.Proceedings of the National Academy of Sciences of the United States of America · 1995Article
- ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors.Breast cancer research and treatment · 1995Article
- The neu-protein and breast cancer.Virchows Archiv : an international journal of pathology · 1995Review
- Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer.Annals of surgery · 1994Article
- bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer.British journal of cancer · 1994Article
- Prognostic significance of c-erbB-2 expression in node negative breast cancer.British journal of cancer · 1993Article
- Construction of immunoradiometric assay for circulating c-erbB-2 protooncogene product in advanced breast cancer patients.Japanese journal of cancer research : Gann · 1993Article
- A retrospective study on the clinical and biological prediction of axillary lymph node metastasis in breast cancer.Surgery today · 1993Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The c-erbB-2 gene codes for a putative transmembrane protein, similar in structure to the epidermal growth factor (EGF) receptor. Amplification of the gene has been described in a variety of human adenocarcinomas and is particularly well documented in breast carcinoma. It has been suggested that amplification is indicative of poor prognosis and, as such, is comparable with lymph node status as a predictor of clinical outcome. This study examines the suggestion indirectly by an immunohistochemical technique. Archival tissue from 195 patients with primary breast carcinoma was stained with the polyclonal antibody 21N, raised to amino acids 1243-1255, the C-terminus of the predicted amino acid sequence of the c-erbB-2 protein. Up to 10 year verified follow-up data were available on all patients. Staining compatible with significant amplification was observed in 17 patients. Using the chi-squared test for trend a significant correlation was found between staining and grade (P = 0.04) but not with either node or receptor status. No significant association was found between staining and clinical outcome although there was a tendency for patients with stained tumours to have a worse prognosis. A Cox regression analysis was used to adjust for node status and grade and still no correlation was revealed between staining and prognosis. However a study of this size in which only a small number of patients have been found to have stained tumours does have wide confidence limits. Comparable staining observed in in situ and infiltrating components of tumours suggests that amplification is an early event in carcinogenesis. Similar staining in primary and subsequent metastatic lesions was also noted. It is considered that further studies at both the DNA/mRNA and protein levels are required to confirm the significance of c-erbB-2 amplification in human breast carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.